

Xifaxan - (550 mg; Tablet, Oral)

Generic Name	Rifaximin	Innovator	SALIX Pharma
Dosage	550 mg; Tablet, Oral	Branded US Sales	More Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	More Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	Indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Xifaxan - (200 mg; Tablet, Oral)

Generic Name	Rifaximin	Innovator	SALIX Pharma
Dosage	200 mg; Tablet, Oral	Branded US Sales	More Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Xifaxan - (550MG)

Generic Name	Rifaximin	Innovator	None
Dosage	550MG	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	XIFAXAN is a rifamycin antibacterial indicated for: • The treatment of patients (? 12 years of age) with travelers' diarrhea caused by noninvasive strains of Escherichia coli. • Reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ? 18 years of age.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.